
Stephen M Montgomery

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6454160/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health Science Reports, 2022, 5, e474.	1.5	3
2	Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. Journal of Medical Economics, 2022, 25, 669-678.	2.1	3
3	RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain. Journal of Medical Economics, 2019, 22, 379-380.	2.1	0
4	When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing–remitting multiple sclerosis. Journal of Medical Economics, 2018, 21, 983-992.	2.1	6
5	Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. Journal of Medical Economics, 2017, 20, 962-973.	2.1	11
6	A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. Journal of Medical Economics, 2017, 20, 474-482.	2.1	17
7	A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence. Clinical Drug Investigation, 2016, 36, 945-956.	2.2	5
8	Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK. Applied Health Economics and Health Policy, 2016, 14, 545-558.	2.1	2
9	The prevalence of child-specific utilities in NICE appraisals for paediatric indications: rise of the economic orphans?. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 347-350.	1.4	9
10	An Undeveloped Picture: The Availability Of Utility Valuations In Latin America – How Will They Affect Qalys?. Value in Health, 2015, 18, A811.	0.3	0
11	Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England?. Value in Health, 2015, 18, A487.	0.3	0
12	Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Journal of Medical Economics, 2015, 18, 874-885.	2.1	23
13	Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Value in Health, 2015, 18, 925-938.	0.3	19
14	Economic orphans? the prevalence of child-specific utilities in nice appraisals for paediatric indications. Value in Health, 2014, 17, A326-A327.	0.3	0
15	Systematic Review and Critique of Health Economic Models on Relapsing-Remitting Multiple Sclerosis in the UK. Value in Health, 2014, 17, A548.	0.3	0